<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63620">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01724437</url>
  </required_header>
  <id_info>
    <org_study_id>PV3503</org_study_id>
    <nct_id>NCT01724437</nct_id>
  </id_info>
  <brief_title>Unexcitability Along the Ablation as an Endpoint for Atrial Fibrillation Ablation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess the near-term (12 months) efficacy of pulmonary vein
      isolation using a standard approach compared to application of an additional acute
      procedural endpoint of unexcitability along the ablation line.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>time to AF recurrence</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>recurrence of AF as assessed by 3 day holter monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time to AT recurrence</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessment of AT recurrence using 3 day holter monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>procedure duration</measure>
    <time_frame>completed (15 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>time needed to complete the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure safety</measure>
    <time_frame>up to three days after the procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>complication such as groin hematoma, stroke and pericardial bleed prolonging the hospital stay will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Catheter Ablation Strategies</condition>
  <arm_group>
    <arm_group_label>Loss of pace capture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>catheter based pulmonary vein isolation</intervention_name>
    <description>catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice</description>
    <arm_group_label>Loss of pace capture</arm_group_label>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  age &gt; 18 years

          -  paroxysmal atrial fibrillation

        Exclusion Criteria:

          -  structural heart disease

          -  intracardiac thrombus

          -  reversible causes of atrial fibrillation

          -  inability to take warfarin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 8, 2012</lastchanged_date>
  <firstreceived_date>November 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Dr. med. Daniel Steven</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
